CTOs on the Move

Ingles Market

www.ingle-markets.com

 
Ingles Market, Inc. is a Albemarle, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Cabrellis

Cabrellis is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Michigan Life Science Network

Michigan Life Science Network is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sun Pharma

Sun Pharma is the world`s fourth largest specialty generic pharmaceutical company and India`s top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma`s global presence is supported by 50 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues.

Sunovion Pharmaceuticals

Sunovion Pharmaceuticals Inc. leads the way to a healthier tomorrow by creating medicines for respiratory diseases and central nervous system disorders.

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.